Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine

PURPOSE There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete...

Full description

Bibliographic Details
Main Authors: Chyla, B. (Author), Dail, M. (Author), DiNardo, C.D (Author), Döhner, H. (Author), Fracchiolla, N.S (Author), Garcia, J.S (Author), Illes, A. (Author), Jang, J.H (Author), Jonas, B.A (Author), Ozcan, M. (Author), Potluri, J. (Author), Pratz, K.W (Author), Pullarkat, V. (Author), Recher, C. (Author), Schuh, A.C (Author), Thirman, M.J (Author), Vorobyev, V. (Author), Yamamoto, K. (Author), Yeh, S.-P (Author), Zhou, Y. (Author)
Format: Article
Language:English
Published: American Society of Clinical Oncology 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items